Turmeric's active compound curcumin has been the subject of hundreds of clinical studies investigating its anti-inflammatory properties, with results promising enough to make it one of the most researched plant-derived compounds in modern pharmacology—even as scientists struggle to solve a fundamental problem with its use as medicine.

Curcumin's anti-inflammatory mechanism operates through multiple pathways simultaneously, inhibiting the NF-κB signaling molecule that activates genes associated with inflammation. This broad-spectrum activity has generated interest for conditions ranging from arthritis to inflammatory bowel disease, and the compound has shown activity in laboratory studies against cancer cells, though the jump from cell cultures to clinical effectiveness in humans has proven difficult to establish reliably.

The primary obstacle to curcumin as a pharmaceutical agent is its poor bioavailability. The human body absorbs it poorly from the gut, and what is absorbed is metabolized quickly. Most of what you consume in turmeric passes through your system without entering the bloodstream in meaningful concentrations.

Researchers have found that combining curcumin with piperine—a compound in black pepper—increases absorption by up to 2,000 percent through inhibition of the metabolic pathway that normally breaks it down. This combination is the basis of most commercially produced curcumin supplements.

For joint pain specifically, several randomized controlled trials have found curcumin supplements comparable to over-the-counter NSAIDs like ibuprofen in reducing pain and improving function in osteoarthritis patients, with fewer gastrointestinal side effects.

The catch is dose: effective doses in clinical trials typically range from 500 to 2,000 milligrams of curcumin daily—far more than is consumed through dietary turmeric. Supplement-level doses, with a bioavailability enhancer, appear genuinely useful. Curry, however much you enjoy it, will not produce the same effect.